Congratulations to Pennovation Works Lab company Interius BioTherapeutics on the announcement of their acquisition!
Kite Pharma, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. They announced that they have entered into a definitive agreement to acquire biotechnology company Interius BioTherapeutics for $350 million.
Interius BioTherapeutics is a clinical stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity and beyond. Leveraging a proprietary platform, Interius has created a differentiated off-the-shelf therapeutic modality designed for broad patient access. The Company’s lead programs aim to overcome the current limitations of ex vivo chimeric antigen receptor (CAR) T-cell therapy by creating therapeutic CAR cells directly in the patient’s body, avoiding preconditioning chemotherapy, manufacturing bottlenecks and high costs.
Congratulations to the Interius team and all involved in the agreement!
